Halozyme Therapeutics (HALO) Competitor Comparison
We are evaluating the key criteria listed to compare Halozyme Therapeutics (HALO) against its competitors in the Biotechnology industry.
Market Capitalization
33 / 368Gross Profits
17 / 278Total Revenue
20 / 300EBITDA
7 / 337Free Cashflow
7 / 352Quick Ratio
155 / 357Earnings per Share
8 / 359Dividend yield
0 / 6Total Cash
65 / 358Performance 3 years
69 / 368Performance 5 years
46 / 368Performance 10 years
19 / 368Linearity 3 years
88 / 368Linearity 5 years
326 / 368Linearity 10 years
364 / 368Total Rank
140 / 368Dividend Rank
40 / 368Valuation Rank
281 / 368Piotroski Rank
165 / 368Muliplier Rank
353 / 368Free Cashflow - HALO ranking 7 / 352
Obligatory risk notice
We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.